Hansoh Pharmaceutical Signs Major Cancer Drug Partnership with Roche

China’s Hansoh Pharmaceutical agreed a licensing partnership with Roche valued at more than $15 billion, announced on 19 October. The agreement includes a $400 million upfront payment, a further $110 million payment after the first year and additional milestone payments tied to the development of cancer therapies.

If you are interested to enquire further, please fill in the form below with your details and one of our consultants will contact you shortly.